TALAPRO-1: Talazoparib monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with tumor DNA damage response alterations (DDRm)—Exploration of germline DDR alteration landscape and ...
Phase 1 Clinical Trial of EVOLVE104 Continues to Advance According to PlanOral Minisymposium Presentation Demonstrates That EVOLVE T Cell ...
In a study published in Proceedings of the National Academy of Sciences, University of Alabama at Birmingham Department of Dermatology professors Chander Raman, Ph.D., and Mohammad Athar, Ph.D., and ...
According to an international multicenter study, CD2-negative mast cells are associated with significantly reduced overall survival in patients with SM. Patients with CD2-negative mast cells have ...
Poster Presentation to Spotlight Ongoing Phase 1 Clinical Trial of EVOLVE104Oral and Poster Presentations to Highlight Preclinical Data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results